US20040241249A1 - Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport - Google Patents

Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport Download PDF

Info

Publication number
US20040241249A1
US20040241249A1 US10/481,040 US48104004A US2004241249A1 US 20040241249 A1 US20040241249 A1 US 20040241249A1 US 48104004 A US48104004 A US 48104004A US 2004241249 A1 US2004241249 A1 US 2004241249A1
Authority
US
United States
Prior art keywords
composition
patient
krill
acid
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/481,040
Other languages
English (en)
Inventor
Tina Sampalis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aker Biomarine Antarctic AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23150259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040241249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/481,040 priority Critical patent/US20040241249A1/en
Assigned to NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. reassignment NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAMPALIS, TINA
Publication of US20040241249A1 publication Critical patent/US20040241249A1/en
Priority to US11/640,235 priority patent/US8057825B2/en
Priority to US13/216,694 priority patent/US20110305771A1/en
Priority to US14/152,603 priority patent/US20140199414A1/en
Priority to US15/267,988 priority patent/US20170224742A1/en
Assigned to AKER BIOMARINE ANTARCTIC AS reassignment AKER BIOMARINE ANTARCTIC AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Neptune Technologies & Bioressources, Inc.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to multi-therapeutic extracts derived from krill and/or marine, which can prevent and/or treat several diseases.
  • Krill is the common name for small, shrimp-like crustaceans, however not shrimp, that swarm in dense shoals, especially in Antarctic waters. It is one of the most important food source for fish, some kind of birds and especially for baleen whales as being an important source of protein. Krill is also a good source of omega-3 fatty acid, which are well known for their health benefits.
  • krill and/or marine oil may be used for the treatment of autoimmune murine lupus and other autoimmune diseases and can also be used for treating cardiovascular diseases.
  • the krill and/or marine oil used for these treatments has only conserved its omega-3 fatty acids as active ingredients, which is a very small part of all the active ingredients of the krill and/or marine itself. This fact reduces the potential of the krill and/or marine oil as a treatment for these diseases.
  • a method of prevention, therapy and/or treatment of several disease comprising the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
  • the krill and/or marine oil is obtained from a process comprising the steps of:
  • the krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Linolenic acid, Alpha-linolenic acid, Linoleic acid, Arachidonic acid, Oleic acid, palmitic acid, palmitoleic acid, stearic acid, nervonic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, Cholesterol, Triglycerides, Monoglycerides, a-tocopherol, all-trans retinol, Astaxanthin, Canthaxanthin, ⁇ -carotene, flavonoid, Zinc, Selenium, sodium, potassium and calcium.
  • the krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Linolenic acid, Alpha-linolenic acid, Linoleic acid, Arachidonic acid, Oleic acid, palmitic acid, palmitoleic acid, stearic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, Cholesterol, Triglycerides, Monoglycerides, a-tocopherol, all-trans retinol, Astaxanthin, Canthaxanthin, ⁇ -carotene, Zinc and Selenium.
  • compositions for the treatment and/or prevention and/or therapy of the previously mentioned diseases comprising a therapeutically effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.
  • a multi-therapeutic oil extract free of enzyme is derived from krill and/or marine, found in any marine environment around the world, for example, the Antarctic ocean (euphasia superba), the Pacific ocean (euphasia pacifica), the Atlantic ocean, the Indian ocean, in particular coastal regions of Mauritius Island and/or Reunion Island of Madagascar, Canadian West Coast, Japanese Coast, St-Lawrence Gulf and Fundy Bay, and this oil extract is a free fatty acid lipid fraction.
  • the active components of the enzyme-free krill and/or marine oil extract are:
  • the neutral lipids of the krill and/or marine extract also comprises:
  • ⁇ -tocopherol (vitamin E) >1.0 IU/100 g
  • ⁇ -carotene >3000 ⁇ g/100 ml
  • Astaxanthin >20 mg/100 g
  • Canthaxanthin >2 mg/100 g
  • the krill and/or marine extract also comprises:
  • Flavonoids >0.5 mg/100 g
  • Oil Stability index ⁇ 0.1 after 50 hours at 97.8° C.
  • Table 1 is showing the results obtained from the previously described tests: TABLE 1 Paired Samples Test Paired Differences 95% Confidence Std. Interval of the Parameter Error Difference Sig. (2- tested Mean SD. Mean Lower Upper t-value df tailed) Cholesterol .4954 .55800 .15476 .1582 .8326 3.201 12 .008 Triglycerides .3538 .54543 .15127 .0242 .6834 2.339 12 .037 HDL ⁇ .2108 .29859 .08281 ⁇ .3912 ⁇ .0303 ⁇ 2.545 12 .026 LDL .2846 .47333 .13128 ⁇ .0014 .5706 2.168 12 .051 Chol/HDL .3600 .53446 .14823 .0370 .6830 2.429 12 .032
  • the inclusion criteria for the study are being aged between 50 and 65 years, both genders being admissible, having a clinical diagnosis of primary osteoarthritis (mild to moderate) 6 to 12 months prior to study enrollment including pain and stiffness, radiographic confirmation of illness prior to enrollment. It also include evidence of measurable symptoms of OA for at least 3 months prior to study enrollment requiring the use of acetaminophen, anti-inflammatory agents or opioid analgesics. Patients were asked to stop the use of all “pain-killers” the week prior to initiation of the trial for wash-out purposes.
  • the Exclusion criteria were a severe osteoarthritis, unavoidable sustained use of NSAID's, aspirin or other medicines for anti-inflammatory use, use of topical analgesics within 4 weeks of randomization visit, steroid injection into either knee within past 3 months, initiation of physical therapy or muscle conditioning within 3 months, seafood allergies, use of anticoagulants or salicylates, alcohol consumption exceeding 3 mixed drinks per day, concurrent medical/arthritic disease that could confound or interfere with the evaluation of pain, prior surgery (including arthroscopy) of either knee, a known “secondary” cause of osteoarthritis.
  • Evaluation was based on daily dose of NSAIDs and/or analgesics and/or SAARDs, number of painful joints, number or swollen joints, duration of morning stiffness, visual analog scale (0-100) WOMACscale and SF36. Preliminary results have been obtained after 2 months. The number of NSAIDs and/or analgesics and/or SAARDs required for daily functioning has been recorded at initiation and at 2 months after initiation.
  • Results shown at Table 2 demonstrate the effect of an uptake of krill extract on the relief of arthritis. TABLE 2 Frequency % Valid % Cumulative % No change 3 23.1 23.1 23.1 Pain relief 10 76.9 76.9 100.0 Total 13 100.0 100.0
  • Nutrition was fat-free chow for the first week and was modified accordingly with the assigned group as described below for the following 2-20 weeks in the quantity of 1 ml of oil per day.
  • mice were divided in six groups as follows:
  • Group E fat free chow (100% of calories)+local application of krill and/or marine oil 2 times per day
  • Group F fat-free chow with supplementation or krill and/or marine oil (20% of total calories)+local application of krill and/or marine oil 2 times per day
  • mice had been submitted to UVB radiation using a fluorescent test lamp, emission spectrum 270400 nm during weeks 2-20.
  • the essay were performed during 30 minutes of UVB exposure per day and the test lamp was at a distance of 30 cm from the mice.
  • mice were anesthetized with ether and sacrificed. Skin was examined blind by pathologists for signs of carcinogenesis.
  • Krill and/or marine oil can be used to enhance transdermal transportation as a substrate for dermatological topical cosmetic applications where cosmetic applications relate to skin hydration, anti-wrinkle, keratolytics, peeling and mask via creams, ointments, gels, lotions or oils.
  • a blood glucose decrease of 20% was obtained for the patients taking krill extract, which shows that an uptake of krill extract is controlling blood glucose content and therefore controlling diabetes in human patients.
US10/481,040 2001-06-18 2002-06-07 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport Abandoned US20040241249A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/481,040 US20040241249A1 (en) 2001-06-18 2002-06-07 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
US11/640,235 US8057825B2 (en) 2001-06-18 2006-12-18 Krill extracts for treatment of cardiovascular diseases
US13/216,694 US20110305771A1 (en) 2001-06-18 2011-08-24 Krill Extracts for Treatment of Cardiovascular Diseases
US14/152,603 US20140199414A1 (en) 2001-06-18 2014-01-10 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
US15/267,988 US20170224742A1 (en) 2001-06-18 2016-09-16 Phospholipid-containing marine extracts for treatment of cardiovascular diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29838301P 2001-06-18 2001-06-18
PCT/CA2002/000843 WO2002102394A2 (en) 2001-06-18 2002-06-07 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
US10/481,040 US20040241249A1 (en) 2001-06-18 2002-06-07 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000843 A-371-Of-International WO2002102394A2 (en) 2001-06-18 2002-06-07 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/640,235 Division US8057825B2 (en) 2001-06-18 2006-12-18 Krill extracts for treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
US20040241249A1 true US20040241249A1 (en) 2004-12-02

Family

ID=23150259

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/481,040 Abandoned US20040241249A1 (en) 2001-06-18 2002-06-07 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
US11/640,235 Expired - Fee Related US8057825B2 (en) 2001-06-18 2006-12-18 Krill extracts for treatment of cardiovascular diseases
US13/216,694 Abandoned US20110305771A1 (en) 2001-06-18 2011-08-24 Krill Extracts for Treatment of Cardiovascular Diseases
US14/152,603 Abandoned US20140199414A1 (en) 2001-06-18 2014-01-10 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
US15/267,988 Abandoned US20170224742A1 (en) 2001-06-18 2016-09-16 Phospholipid-containing marine extracts for treatment of cardiovascular diseases

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/640,235 Expired - Fee Related US8057825B2 (en) 2001-06-18 2006-12-18 Krill extracts for treatment of cardiovascular diseases
US13/216,694 Abandoned US20110305771A1 (en) 2001-06-18 2011-08-24 Krill Extracts for Treatment of Cardiovascular Diseases
US14/152,603 Abandoned US20140199414A1 (en) 2001-06-18 2014-01-10 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
US15/267,988 Abandoned US20170224742A1 (en) 2001-06-18 2016-09-16 Phospholipid-containing marine extracts for treatment of cardiovascular diseases

Country Status (14)

Country Link
US (5) US20040241249A1 (ja)
EP (2) EP1406641B1 (ja)
JP (4) JP5135568B2 (ja)
CN (2) CN1516592A (ja)
AT (2) ATE419858T1 (ja)
CA (1) CA2449898C (ja)
CY (1) CY1108986T1 (ja)
DE (1) DE60230759D1 (ja)
DK (2) DK1406641T3 (ja)
ES (2) ES2321066T3 (ja)
HK (2) HK1126957A1 (ja)
NO (1) NO332690B1 (ja)
PT (1) PT1406641E (ja)
WO (1) WO2002102394A2 (ja)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080515A1 (en) * 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
US20080274203A1 (en) * 2007-03-28 2008-11-06 Aker Biomarine Asa Bioeffective krill oil compositions
WO2009027692A2 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa A new method for making krill meal
US20100227792A1 (en) * 2009-02-26 2010-09-09 Aker Biomarine Asa Phospholipid and protein tablets
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
WO2011011604A2 (en) 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain
US20110195061A1 (en) * 2009-07-23 2011-08-11 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
US20110224450A1 (en) * 2009-10-30 2011-09-15 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
WO2011137160A2 (en) 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
AU2013227998A1 (en) * 2007-03-28 2013-09-26 Aker Biomarine Antarctic As Bioeffective krill oil compositions
AU2012244229B2 (en) * 2007-08-29 2013-11-21 Aker Biomarine Antarctic As A new method for making krill meal
EP2683253A1 (en) * 2011-03-07 2014-01-15 Olympic Seafood AS Compositions and methods for nutritional supplementation
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9107891B2 (en) 2011-06-29 2015-08-18 Nippon Suisan Kaisha, Ltd. Method for alleviating fear memory
WO2015142705A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using algae based oils
WO2015143001A1 (en) 2014-03-19 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Therapeutic astaxanthin and phospholipid composition and associated method
WO2015142702A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and roe extract
WO2015142700A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9192671B2 (en) 2010-04-30 2015-11-24 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
AU2014256341B2 (en) * 2007-08-29 2016-04-14 Aker Biomarine Antarctic As A new method for making krill meal
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
US9867856B2 (en) 2014-01-10 2018-01-16 Aker Biomarine Antarctic As Phospholipid compositions and their preparation
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
DE202018105422U1 (de) 2018-06-21 2018-10-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
DE202018105987U1 (de) 2018-05-24 2018-12-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
US10456412B2 (en) 2015-02-11 2019-10-29 Aker Biomarine Antarctic As Lipid extraction processes
US10493086B2 (en) 2016-06-29 2019-12-03 Machavert Pharmaceuticals Llc Phospholipid compositions
US10704011B2 (en) 2013-06-14 2020-07-07 Aker Biomarine Antarctic As Lipid extraction processes
US10864223B2 (en) 2015-02-11 2020-12-15 Aker Biomarine Antarctic As Lipid compositions
WO2022050819A1 (ko) * 2020-09-07 2022-03-10 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030348B2 (en) 2001-07-27 2011-10-04 Neptune Technologies & Bioressources, Inc. Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
AU2013205514B2 (en) * 2001-07-27 2015-07-02 Aker Biomarine Antarctic As Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US7968529B2 (en) 2003-01-20 2011-06-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0314624D0 (en) 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
FR2859380B1 (fr) * 2003-09-05 2006-02-10 Phythea Composition destinee au traitement cosmetique de la peau d'un etre humain
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
EP1682077A4 (en) 2003-10-28 2009-07-01 Univ Emory DIALYSATS AND CORRESPONDING METHODS AND SYSTEMS
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1727882A4 (en) * 2004-02-06 2008-12-10 Adrien Beaudoin PROCESS FOR PREVENTING OXIDATION OF LIPIDS IN ANIMAL AND VEGETABLE OILS AND COMPOSITIONS PRODUCED ACCORDING TO SAID METHOD
EP1729597B1 (en) * 2004-03-16 2011-03-09 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
AU2005310341A1 (en) 2004-11-30 2006-06-08 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
JP2006016408A (ja) * 2005-06-23 2006-01-19 Yamaha Motor Co Ltd 血中中性脂肪抑制剤
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2007045407A2 (en) * 2005-10-18 2007-04-26 Artmed S.R.L. Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma
AU2007271900B2 (en) * 2006-07-14 2013-05-23 Nattopharma As Pharmaceutical and nutraceutical products comprising vitamin K2
CN101646426A (zh) * 2006-11-03 2010-02-10 普罗诺瓦生物医药挪威公司 ω-3脂质化合物
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
AU2014100740B4 (en) * 2007-03-28 2014-11-20 Aker Biomarine Antarctic As Processes and products thereof
US8911888B2 (en) 2007-12-16 2014-12-16 HGST Netherlands B.V. Three-dimensional magnetic memory with multi-layer data storage layers
US8586104B2 (en) * 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
CA2724463C (en) * 2008-05-15 2017-10-03 Pronova Biopharma Norge As Krill oil process
WO2010028336A2 (en) * 2008-09-08 2010-03-11 President And Fellows Of Harvard College Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
US9814256B2 (en) 2009-09-14 2017-11-14 Rimfrost Technologies As Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof
DK3516966T3 (da) 2008-09-12 2023-02-13 Rimfrost Tech As Koncentreret krillproteinhydrolysatfraktion
US8557297B2 (en) 2008-09-12 2013-10-15 Olympic Seafood, As Method for processing crustaceans and products thereof
KR101024491B1 (ko) * 2008-12-31 2011-03-31 인성실업(주) 해양 동물로부터 지질을 추출하는 방법
JP2010241710A (ja) * 2009-04-02 2010-10-28 Japan Health Science Foundation Ａｃｅ２活性誘導剤
US9925162B2 (en) 2009-04-09 2018-03-27 The Regents Of The University Of Colorado Methods and compositions for inducing physiological hypertrophy
EP2435055A2 (en) 2009-05-28 2012-04-04 Aker Biomarine ASA Methods of using krill oil to treat risk factors for metabolic disorders and obesity
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
KR101788342B1 (ko) * 2009-10-29 2017-10-19 아카스티 파마, 인크. 농축된 치료용 인지질 조성물
MX2012005460A (es) * 2009-11-11 2012-07-20 Dynasep Inc Metodo de secado con acetona eficiente en energia.
US20110117207A1 (en) * 2009-11-17 2011-05-19 U.S. Nutraceuticals, LLC d/b/a Valensa International State of Incorporation: Use of eggshell membrane formulations to alleviate joint pain
WO2012029898A1 (ja) * 2010-09-01 2012-03-08 日本水産株式会社 アルコール性障害緩和剤
KR20120051458A (ko) * 2010-11-12 2012-05-22 주식회사 두산 크릴 인지질을 이용하여 아스타잔틴 및 ｄｈａ－ 및/또는 ｅｐａ－결합된 포스파티딜세린을 함유한 조성물을 제조하는 방법 및 이러한 방법에 의해 제조된 조성물
CN102485899A (zh) * 2010-12-03 2012-06-06 张永志 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法
CN102041166B (zh) * 2011-01-20 2012-05-23 山东师范大学 从南极磷虾中提取高磷脂含量的虾油的方法
WO2012103685A1 (en) * 2011-02-01 2012-08-09 Nippon Suisan Kaisha, Ltd. Sexual function improving agent
KR101045258B1 (ko) * 2011-02-11 2011-06-30 대덕에프알디(주) 크릴 오일 제조 방법 및 상기 방법에 의해 제조된 크릴 오일
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
HUE036720T2 (hu) * 2011-06-15 2018-07-30 Stable Solutions Llc Parenterális krill olaj terápiás alkalmazása
CA2839507A1 (en) * 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
CA2860512C (en) 2012-01-06 2019-02-05 Omthera Pharmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
CN102559371B (zh) * 2012-02-21 2013-09-18 山东师范大学 一种制备富含磷脂酰丝氨酸的虾油的方法
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
US10190952B2 (en) 2012-09-07 2019-01-29 Japan Science And Technology Agency Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
CN102899164B (zh) * 2012-10-25 2015-12-02 山东师范大学 一种制备无氟南极磷虾虾油的工艺
CN102899162B (zh) * 2012-10-25 2013-12-04 山东师范大学 一种制备低氟含量的南极磷虾虾油的工艺
CN102911786B (zh) * 2012-10-25 2014-01-08 山东师范大学 一种从南极磷虾中提取低氟含量的虾油的工艺
CN102899163B (zh) * 2012-10-25 2015-03-25 山东师范大学 一种从南极磷虾中提取无氟虾油的工艺
CN102925284B (zh) * 2012-10-25 2014-01-08 山东师范大学 一种从南极磷虾中提取低胆固醇含量的虾油的工艺
WO2014184655A1 (en) 2013-02-07 2014-11-20 Olympic Seafood As Methods for using crustacean phospholipid-peptide-protein complexes
EP3056090A4 (en) 2013-10-08 2017-04-26 Taiyo Kagaku Co., Ltd. Oil/fat composition containing polyunsaturated fatty acid
JP6393501B2 (ja) * 2014-04-03 2018-09-19 太陽化学株式会社 多価不飽和脂肪酸含有油脂の風味改善剤
JP2015096488A (ja) * 2013-10-10 2015-05-21 康二 嘉島 終末糖化物質生成抑制方法
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
WO2015181640A1 (en) * 2014-04-30 2015-12-03 Enzymotec Ltd. Krill oil preparations and their uses
JP6299689B2 (ja) * 2014-07-24 2018-03-28 三生医薬株式会社 生体吸収促進剤含有組成物
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Aseko, Inc. Subcutaneous outpatient management
US10328105B2 (en) 2015-05-27 2019-06-25 Rimfrost Technologies As Flowable concentrated phospholipid krill oil composition
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
CN105341184A (zh) * 2015-10-14 2016-02-24 中国农业科学院油料作物研究所 一种具有预防心脑血管疾病和糖尿病风险因子作用的功能性油脂组合物
BR122022002021B1 (pt) * 2015-12-14 2023-03-14 Société des Produits Nestlé S.A. Composição nutricional sintética, seu uso e mineral
DE202015106826U1 (de) * 2015-12-15 2016-02-03 Wolfgang Braun Zusammensetzung zur Behandlung von Prämenstruellem Syndrom
JP2019534329A (ja) * 2016-11-04 2019-11-28 アイエムエムディー エスペー．ゾー．オー 摂取および吸収された分子の知的送達
JP7309136B2 (ja) * 2017-04-14 2023-07-18 学校法人帝京大学 Ｈｄｌ機能改善剤及びｈｄｌ機能改善食品組成物
DK3727404T3 (da) * 2017-12-22 2023-10-09 Pharmalink International Ltd Sammensætninger omfattende muslingelipidekstrakt og krillolie, og deres medicinske anvendelser
JP2019210239A (ja) * 2018-06-02 2019-12-12 学校法人 岩手医科大学 ８−ヒドロキシエイコサペンタエン酸の薬理用途
BR112021004809A2 (pt) * 2018-06-28 2021-06-22 Marizyme Biotech composições farmacêuticas e métodos para o tratamento de trombose e aplicação por dispositivos médicos
US20220265291A9 (en) * 2018-06-28 2022-08-25 Marizyme, Inc. Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
KR102085506B1 (ko) * 2018-07-25 2020-03-05 이경희 두피자극완화용 염모제 첨가조성물 및 두피자극완화용 염모제
EP4087582A1 (en) * 2020-01-10 2022-11-16 Acasti Pharma Inc. Composition that promote pro-resolving mediators
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale
CN112315984B (zh) * 2020-09-09 2023-02-14 山东省科学院生物研究所 海洋来源磷脂在促进血管生成方面的应用
CN112494499B (zh) * 2020-12-14 2022-01-28 山东省科学院生物研究所 海洋磷脂作为有效成分在制备预防和/或治疗心脏疾病药物中的应用
AU2022224703A1 (en) * 2021-09-28 2023-04-13 Samuel L. Shepherd Tetraterpenes for use in cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265450B1 (en) * 1995-10-26 2001-07-24 Suntory Limited Anti-stress composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119017A (en) * 1978-03-06 1979-09-14 Taiyo Fishery Co Ltd Protective agent for hypertensive disease and production
JPS60153779A (ja) 1984-01-24 1985-08-13 Hohnen Oil Co Ltd 栄養補助食品
JPS6130527A (ja) * 1984-07-20 1986-02-12 Kao Corp 血栓溶解剤
JPS61118318A (ja) * 1984-11-12 1986-06-05 Pola Chem Ind Inc 血清脂質改善用組成物
JPS63295698A (ja) * 1987-05-27 1988-12-02 Showa Denko Kk α−リノレン酸の分離精製法
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
JPH01137952A (ja) * 1987-11-20 1989-05-30 Nippon Suisan Kaisha Ltd 健康食品
JPH02167055A (ja) * 1988-12-19 1990-06-27 Seiji Nojima 機能性練製品
JPH03123470A (ja) * 1989-10-05 1991-05-27 Taiyo Fishery Co Ltd オキアミ中のアンジオテンシン変換酵素阻害活性の増強法
JP2558050B2 (ja) * 1993-02-18 1996-11-27 イセ食品株式会社 鶏用飼料
JPH08219A (ja) * 1994-06-15 1996-01-09 Nippon Synthetic Chem Ind Co Ltd:The 機能の改善された油組成物
JP2666179B2 (ja) * 1994-08-10 1997-10-22 財団法人韓國食品開發研究院 抗高血圧健康食品組成物
JP3664814B2 (ja) * 1996-06-26 2005-06-29 旭化成ケミカルズ株式会社 血中脂質改善剤及び食品添加剤
JP3118556B2 (ja) * 1996-09-27 2000-12-18 中央水産研究所長 魚肉水溶性タンパク質により油脂を高濃度に含有させた魚肉乳化すり身及びその製造法
CA2251265A1 (en) * 1998-10-21 2000-04-21 Universite De Sherbrooke Process for lipid extraction of aquatic animal tissues producing a dehydrated residue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265450B1 (en) * 1995-10-26 2001-07-24 Suntory Limited Anti-stress composition

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080515A1 (en) * 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
US9730966B2 (en) 2007-03-28 2017-08-15 Aker Biomarine Antartic As Method of reducing appetite in a human subject comprising administering krill oil composition
US10543237B2 (en) 2007-03-28 2020-01-28 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9034388B2 (en) 2007-03-28 2015-05-19 Aker Biomarine Antartic As Bioeffective krill oil compositions
US9072752B1 (en) 2007-03-28 2015-07-07 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9078905B2 (en) 2007-03-28 2015-07-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US11865143B2 (en) 2007-03-28 2024-01-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9644169B2 (en) 2007-03-28 2017-05-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US10010567B2 (en) 2007-03-28 2018-07-03 Aker Biomarine Antarctic As Bioeffective krill oil compositions
AU2013227998A1 (en) * 2007-03-28 2013-09-26 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9889163B2 (en) 2007-03-28 2018-02-13 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9119864B2 (en) 2007-03-28 2015-09-01 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9816046B2 (en) 2007-03-28 2017-11-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9220735B2 (en) 2007-03-28 2015-12-29 Aker Biomarine Antarctic As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20080274203A1 (en) * 2007-03-28 2008-11-06 Aker Biomarine Asa Bioeffective krill oil compositions
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20140010888A1 (en) * 2007-03-28 2014-01-09 Aker Biomarine As Bioeffective krill oil compositions
US9320765B2 (en) * 2007-03-28 2016-04-26 Aker Biomarine Antarctic As Bioeffective krill oil compositions
AU2013227998C1 (en) * 2007-03-28 2018-03-08 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9644170B2 (en) 2007-03-28 2017-05-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9375453B2 (en) 2007-03-28 2016-06-28 Aker Biomarine Antarctic As Methods for producing bioeffective krill oil compositions
CN103815114A (zh) * 2007-08-29 2014-05-28 阿克海洋生物股份公司 新的制备磷虾粉的方法
WO2009027692A2 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa A new method for making krill meal
KR101343290B1 (ko) * 2007-08-29 2013-12-18 에이커 바이오마린 에이에스 새로운 크릴 밀 제조 방법
AU2014256341B2 (en) * 2007-08-29 2016-04-14 Aker Biomarine Antarctic As A new method for making krill meal
AU2012244229B2 (en) * 2007-08-29 2013-11-21 Aker Biomarine Antarctic As A new method for making krill meal
AU2014256341C1 (en) * 2007-08-29 2017-08-24 Aker Biomarine Antarctic As A new method for making krill meal
AU2008291978B2 (en) * 2007-08-29 2012-08-09 Aker Biomarine Antarctic As A new method for making krill meal
EP2732709A1 (en) * 2007-08-29 2014-05-21 Aker BioMarine AS A new method for making krill meal
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
WO2009027692A3 (en) * 2007-08-29 2009-05-14 Aker Biomarine Asa A new method for making krill meal
US20090061067A1 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa Method for making krill meal
US20100227792A1 (en) * 2009-02-26 2010-09-09 Aker Biomarine Asa Phospholipid and protein tablets
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US9795631B2 (en) 2009-07-23 2017-10-24 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US9028814B2 (en) 2009-07-23 2015-05-12 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9034366B2 (en) 2009-07-23 2015-05-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8999373B2 (en) 2009-07-23 2015-04-07 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9050364B2 (en) 2009-07-23 2015-06-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8962924B2 (en) 2009-07-23 2015-02-24 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8945608B2 (en) 2009-07-23 2015-02-03 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
EP2902033A1 (en) 2009-07-23 2015-08-05 U.S. Nutraceuticals LLC dba Valensa International Composition and method to alleviate joint pain
WO2011011604A2 (en) 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain
US8524980B2 (en) 2009-07-23 2013-09-03 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US10624919B2 (en) 2009-07-23 2020-04-21 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US20110195061A1 (en) * 2009-07-23 2011-08-11 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
US9597305B2 (en) 2009-07-23 2017-03-21 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9999631B2 (en) 2009-07-23 2018-06-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9974756B2 (en) 2009-07-23 2018-05-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9597300B2 (en) 2009-07-23 2017-03-21 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9675635B2 (en) 2009-07-23 2017-06-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and joint care components, including type II collagen
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8507757B2 (en) 2009-07-23 2013-08-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
DE202010017863U1 (de) 2009-07-23 2012-11-23 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
DE202010018054U1 (de) 2009-07-23 2013-10-18 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US8609157B2 (en) 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US8772516B2 (en) 2009-10-30 2014-07-08 Tharos. Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US9011942B2 (en) 2009-10-30 2015-04-21 Tharos, Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US9150815B2 (en) 2009-10-30 2015-10-06 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US20110224450A1 (en) * 2009-10-30 2011-09-15 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US8865236B2 (en) 2009-10-30 2014-10-21 Tharos Ltd. Solvent-Free Process for Obtaining Phospholipids and Neutral Enriched Krill Oils
US9192671B2 (en) 2010-04-30 2015-11-24 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
WO2011137160A2 (en) 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
DE202011110338U1 (de) 2010-07-21 2013-07-09 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zum Lindern von Gelenkschmerzen unter Verwendung eines Gemischs aus Fischöl und einem von Fischöl stammenden, auf Cholin beruhenden, an Phospholipid gebunden Fettsäuregemisch beinhaltend mehrfach ungesättigte EPA und DHA
WO2012012372A1 (en) 2010-07-21 2012-01-26 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
EP2683253A1 (en) * 2011-03-07 2014-01-15 Olympic Seafood AS Compositions and methods for nutritional supplementation
US9107891B2 (en) 2011-06-29 2015-08-18 Nippon Suisan Kaisha, Ltd. Method for alleviating fear memory
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10039734B2 (en) 2012-12-24 2018-08-07 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US11578289B2 (en) 2013-06-14 2023-02-14 Aker Biomarine Antarctic As Lipid extraction processes
US10704011B2 (en) 2013-06-14 2020-07-07 Aker Biomarine Antarctic As Lipid extraction processes
US9867856B2 (en) 2014-01-10 2018-01-16 Aker Biomarine Antarctic As Phospholipid compositions and their preparation
WO2015142702A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and roe extract
WO2015142705A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using algae based oils
WO2015142707A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
DE212015000073U1 (de) 2014-03-18 2016-12-06 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zum Mildern von Gelenkschmerzen mittels Phopholipiden und Astaxanthin
DE212015000076U1 (de) 2014-03-18 2016-12-06 U.S. Nutraceuticals Llc Dba Valensa International Zusammensetzung zum Mildern von Gelenkschmerzen mittels niedermolekulargewichtiger Hyaluronsäure und Astaxanthin
WO2015142700A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and astaxanthin
WO2015143001A1 (en) 2014-03-19 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Therapeutic astaxanthin and phospholipid composition and associated method
WO2015142999A1 (en) 2014-03-19 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin
DE212015000033U1 (de) 2014-03-19 2016-08-26 U.S. Nutraceuticals, Llc D/B/A Valensa International Therapeutische Astaxanthin- und Phospholipidzusammensetzung
US10456412B2 (en) 2015-02-11 2019-10-29 Aker Biomarine Antarctic As Lipid extraction processes
US11819509B2 (en) 2015-02-11 2023-11-21 Aker Biomarine Antarctic As Lipid compositions
US10864223B2 (en) 2015-02-11 2020-12-15 Aker Biomarine Antarctic As Lipid compositions
US10493086B2 (en) 2016-06-29 2019-12-03 Machavert Pharmaceuticals Llc Phospholipid compositions
US11433085B2 (en) 2016-06-29 2022-09-06 Machavert Pharmaceuticals, Llc Phospholipid compositions
WO2019226186A1 (en) 2018-05-24 2019-11-28 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using hyaluronic acid and eggshell membrane components
DE202018105987U1 (de) 2018-05-24 2018-12-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
DE202018105422U1 (de) 2018-06-21 2018-10-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
KR20220033554A (ko) * 2020-09-07 2022-03-17 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물
KR102451162B1 (ko) * 2020-09-07 2022-10-06 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물
WO2022050819A1 (ko) * 2020-09-07 2022-03-10 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물

Also Published As

Publication number Publication date
US20110305771A1 (en) 2011-12-15
EP1997498B1 (en) 2012-04-25
ES2386841T3 (es) 2012-09-03
CN102319266B (zh) 2014-12-17
EP1997498A3 (en) 2009-06-03
DK1997498T3 (da) 2012-07-30
CN1516592A (zh) 2004-07-28
CN102319266A (zh) 2012-01-18
ATE554779T1 (de) 2012-05-15
JP5135568B2 (ja) 2013-02-06
US20140199414A1 (en) 2014-07-17
JP2010090141A (ja) 2010-04-22
CA2449898A1 (en) 2002-12-27
EP1406641B1 (en) 2009-01-07
DE60230759D1 (de) 2009-02-26
WO2002102394A2 (en) 2002-12-27
CY1108986T1 (el) 2014-07-02
DK1406641T3 (da) 2009-05-04
ES2321066T3 (es) 2009-06-02
HK1126957A1 (en) 2009-09-18
CA2449898C (en) 2018-03-06
PT1406641E (pt) 2009-04-15
NO332690B1 (no) 2012-12-10
JP5228185B2 (ja) 2013-07-03
EP1997498A2 (en) 2008-12-03
WO2002102394A3 (en) 2003-04-10
US20070098808A1 (en) 2007-05-03
JP2004534800A (ja) 2004-11-18
NO20035618D0 (no) 2003-12-16
US20170224742A1 (en) 2017-08-10
JP2010090140A (ja) 2010-04-22
US8057825B2 (en) 2011-11-15
JP2013079278A (ja) 2013-05-02
ATE419858T1 (de) 2009-01-15
HK1165729A1 (en) 2012-10-12
EP1406641A2 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
US8057825B2 (en) Krill extracts for treatment of cardiovascular diseases
JP3008213B2 (ja) 医薬組成物
US7666447B2 (en) Compositions including Krill extracts and conjugated linoleic acid and methods of using same
EP1871399B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
RU2366412C2 (ru) Композиции и способы лечения гиперпролиферативных состояний кожи
US8535696B2 (en) Treating eczema and/or psoriasis
US20040091506A1 (en) Topical antifungal treatment
US11039997B2 (en) Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound
EP1965791B1 (de) Neue kompositionen gegen alkyl-acyl-gpc, seine derivate und produkte
Lieberman Natural Interventions for Treating Psoriasis

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAMPALIS, TINA;REEL/FRAME:015549/0970

Effective date: 20040405

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: AKER BIOMARINE ANTARCTIC AS, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEPTUNE TECHNOLOGIES & BIORESSOURCES, INC.;REEL/FRAME:043525/0925

Effective date: 20170905